Urolog. pro Praxi, 2008; 9(1): 8-9
Erectile dysfunction - new preferences in treatment?
- Urologická klinika 1. LF UK a VFN Praha
The development of the first 5-phosphodiesterase inhibitor (sildenafil) and its introduction into routine clinical practice was a major breakthrough in the quality of treatment for such a tabooed issue as erectile dysfunction. Since then, the attitudes of both the society and the physicians towards this symptom have changed. Diagnosis and treatment of sexual dysfunctions have improved due to educational campaigns. Over time, however, other preparations have become available on the market. These not only differ in price (which, for some patients, may be a decisive factor in selection) but also in their pharmacological profile and effect. Any physician involved in diagnosing and treating erectile dysfunctions should be familiar with the effects of the drugs and, based on the patient‘s preferences, recommend the one which appears most suitable.
Keywords: erectile dysfunction, preferences, 5-phosphodiesterase inhibitors
Published: April 1, 2008 Show citation
References
- Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, Lang C, Horner R, Gutkin S, Dickson R. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. BJU Int 2007; 99: 376-382.
Go to original source... 
Go to PubMed... - Carson CC. PDE5 inhibitors: are there differences? Can J Urol 2006; 13 Suppl 1: 34-39.
- Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int 2007; 99: 860-863. Go to original source... Go to PubMed...
- Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 39-57. Go to original source... Go to PubMed...
- Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Urology 2006; 68: 26-37. Go to original source... Go to PubMed...
- Mulhall J, Althof SE, Brock GB, Goldstein I, Junemann KP, Kirby M. Erectile dysfunction: monitoring response to treatment in clinical practice-recommendations of an international study panel. J Sex Med 2007; 4: 448-464. Go to original source... Go to PubMed...
- Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the Erection Hardness Score. J Sex Med 2007; 4: 1626-1634. Go to original source... Go to PubMed...
- Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005; 2: 848-855. Go to original source... Go to PubMed...
- Sivalingam S, Hashim H, Schwaibold H. An overview of the diagnosis and treatment of erectile dysfunction. Drugs 2006; 66: 2339-2355. Go to original source... Go to PubMed...
- Wespes E. Erectile dysfunction, physiologic approach, diagnosis and therapy. Bull Mem Acad R Med Belg 2006; 161: 151-158.
- Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806-815. Go to original source... Go to PubMed...